These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 12584738)

  • 21. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2.
    Yamasaki S; Nishida K; Yoshida Y; Itoh M; Hibi M; Hirano T
    Oncogene; 2003 Mar; 22(10):1546-56. PubMed ID: 12629518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of Raf-1 kinase by TNF via its second messenger ceramide and cross-talk with mitogenic signalling.
    Müller G; Storz P; Bourteele S; Döppler H; Pfizenmaier K; Mischak H; Philipp A; Kaiser C; Kolch W
    EMBO J; 1998 Feb; 17(3):732-42. PubMed ID: 9450998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells.
    Lee JT; Steelman LS; McCubrey JA
    Int J Oncol; 2005 Jun; 26(6):1637-44. PubMed ID: 15870880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Raf revealed in life-or-death decisions.
    Pritchard C; McMahon M
    Nat Genet; 1997 Jul; 16(3):214-5. PubMed ID: 9207779
    [No Abstract]   [Full Text] [Related]  

  • 27. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo.
    Hall-Jackson CA; Goedert M; Hedge P; Cohen P
    Oncogene; 1999 Mar; 18(12):2047-54. PubMed ID: 10321729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Negative regulation of mitochondrial VDAC channels by C-Raf kinase.
    Le Mellay V; Troppmair J; Benz R; Rapp UR
    BMC Cell Biol; 2002 Jun; 3():14. PubMed ID: 12079506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IFN-gamma production from human Th1 cells is controlled by Raf kinase.
    Webber S; Zheng R; Kamal A; Withnall M; Karlsson JA
    Int Arch Allergy Immunol; 1997; 113(1-3):275-8. PubMed ID: 9130547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases.
    Rapp UR; Rennefahrt U; Troppmair J
    Biochim Biophys Acta; 2004 Mar; 1644(2-3):149-58. PubMed ID: 14996499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raf and the road to cell survival: a tale of bad spells, ring bearers and detours.
    Troppmair J; Rapp UR
    Biochem Pharmacol; 2003 Oct; 66(8):1341-5. PubMed ID: 14555207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway.
    O'Neill EE; Matallanas D; Kolch W
    Cancer Res; 2005 Jul; 65(13):5485-7. PubMed ID: 15994916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-RAF function at the genome-wide transcriptome level: A systematic view.
    Huang Y; Zhang XY; An S; Yang Y; Liu Y; Hao Q; Guo XX; Xu TR
    Gene; 2018 May; 656():53-59. PubMed ID: 29499332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment.
    Cho-Chung YS
    Pharmacol Ther; 1999; 82(2-3):437-49. PubMed ID: 10454218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense therapy in clinical oncology: preclinical and clinical experiences.
    Tamm I
    Methods Mol Med; 2005; 106():113-34. PubMed ID: 15375315
    [No Abstract]   [Full Text] [Related]  

  • 37. Raf kinases in lung tumor development.
    Rapp UR; Fensterle J; Albert S; Götz R
    Adv Enzyme Regul; 2003; 43():183-95. PubMed ID: 12791391
    [No Abstract]   [Full Text] [Related]  

  • 38. Vascular Stem Cells and the Role of B-Raf Kinase in Survival, Proliferation, and Apoptosis.
    Goyal D; Limesand SW; Goyal R
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanisms of mouse skin tumor promotion.
    Rundhaug JE; Fischer SM
    Cancers (Basel); 2010; 2(2):436-82. PubMed ID: 21297902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raf-1 activation prevents caspase 9 processing downstream of apoptosome formation.
    Cagnol S; Mansour A; Van Obberghen-Schilling E; Chambard JC
    J Signal Transduct; 2011; 2011():834948. PubMed ID: 21637382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.